SAR442168
Drug
GENZYME CORPORATION
Total Payments
$813,607
Transactions
70
Doctors
6
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $813,607 | 70 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $813,607 | 70 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis | GENZYME CORPORATION | $702,812 | 1 |
| Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis | GENZYME CORPORATION | $70,301 | 1 |
| A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis | SANOFI US SERVICES INC. | $39,700 | 5 |
| A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis | GENZYME CORPORATION | $795.00 | 2 |
Top Doctors Receiving Payments for SAR442168
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cincinnati, OH | $646,449 | 44 |
| , M.D | Specialist | Maitland, FL | $133,966 | 8 |
| , MD | Neurology | Knoxville, TN | $9,342 | 5 |
| , M.D | Neurology | Guntersville, AL | $8,981 | 4 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Savannah, GA | $7,396 | 4 |
| , M.D | Epilepsy | Northbrook, IL | $7,075 | 4 |
| , MD | Neurology | Cullman, AL | $397.50 | 1 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $773,907
- SANOFI US SERVICES INC. $39,700
Product Information
- Type Drug
- Total Payments $813,607
- Total Doctors 6
- Transactions 70
About SAR442168
SAR442168 is a drug associated with $813,607 in payments to 6 healthcare providers, recorded across 70 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2019 to 2019. In 2019, $813,607 was paid across 70 transactions to 6 doctors.
The most common payment nature for SAR442168 is "Unspecified" ($813,607, 100.0% of total).
SAR442168 is associated with 4 research studies, including "A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis" ($702,812).